

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

### How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

**Why is a particular medicine not routinely available in NHS Grampian?**

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

**What happens if a particular medicine is not routinely available in NHS Grampian?**

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email [gram.formularyteam@nhs.scot](mailto:gram.formularyteam@nhs.scot).

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](https://www.freepressphotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Advagraf® 0.5mg, 1mg, 3mg, 5mg prolonged-release hard capsules (tacrolimus)	<a href="#">402/07</a>	Prophylaxis of transplant rejection in adult kidney allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Not routinely available as there is a local preference for alternative medicines	18/03/2025
amivantamab 350mg concentrate for solution for infusion (Rybrevant®)	<a href="#">2768</a>	In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).	Not routinely available as not recommended for use in NHS Scotland, SMC 2768 <a href="https://scottishmedicines.org.uk/media/9020/amivantamab-rybrevant-non-sub-final-feb-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9020/amivantamab-rybrevant-non-sub-final-feb-2025-for-website.pdf</a>	18/03/2025
atezolizumab 840mg, 1,200mg concentrate for solution for infusion, 1,875mg solution for injection (Tecentriq®)	<a href="#">2769</a>	As monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2769 <a href="https://scottishmedicines.org.uk/media/9021/atezolizumab-tecentriq-non-sub-final-feb-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9021/atezolizumab-tecentriq-non-sub-final-feb-2025-for-website.pdf</a>	18/03/2025
Biotene® Oralbalance Gel		Symptomatic treatment of dry mouth.	Not routinely available as there is a local preference for alternative medicines	18/03/2025
cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabozantinib Ipsen)	<a href="#">2754</a>	As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/03/2025
Dailiport® 0.5mg, 1mg, 2mg, 3mg, 5mg prolonged-release hard capsules (tacrolimus)		Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults.	Routinely available in line with local guidance	18/03/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
mavacamten 2.5mg, 5mg, 10mg, 15mg hard capsules (Camzyos®)	<a href="#">2618</a>	For the treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adults. <b>Restriction:</b> as add on to individually optimised standard care (with beta-blockers, non-dihydropyridine calcium channel blockers or disopyramide), unless these are contraindicated, ineffective or poorly tolerated.	Routinely available in line with national guidance, SMC 2618 <a href="https://scottishmedicines.org.uk/media/8226/mavacamten-camzyos-final-march-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8226/mavacamten-camzyos-final-march-2024-for-website.pdf</a>	18/03/2025
Metyrol® XL 10mg, 20mg, 30mg, 40mg, 60mg modified-release hard capsules (methylphenidate)		As part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents between the age of 6 and 18 years when remedial measures alone prove insufficient.	Routinely available in line with local guidance	18/03/2025
Oralieve® Moisturising Mouth Gel, Spray		Children, adolescents and adults age 12 years and older for the symptomatic treatment of dry mouth.	Routinely available in line with local guidance	18/03/2025
pomalidomide 1mg, 2mg, 3mg, 4mg hard capsules	<a href="#">119</a>	[Off-label use] in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior treatment regimen including lenalidomide, and where more effective alternatives are not suitable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/03/2025
pomalidomide 1mg, 2mg, 3mg, 4mg hard capsules	<a href="#">120</a>	In combination with bortezomib plus dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/03/2025
ripretinib 50mg tablets (Qinlock®)	<a href="#">2722</a>	For the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Not routinely available as not recommended for use in NHS Scotland, SMC 2722 <a href="https://scottishmedicines.org.uk/media/9017/riporetinib-tablets-qinlock-final-feb-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9017/riporetinib-tablets-qinlock-final-feb-2025-for-website.pdf</a>	18/03/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Ritalin® XL 10mg, 20mg, 30mg, 40mg, 60mg modified-release hard capsules (methylphenidate)		As part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents between the age of 6 and 18 years when remedial measures alone prove insufficient.	Routinely available in line with local guidance	18/03/2025
spesolimab 450mg concentrate for solution for infusion (Spevigo®)	<a href="#">2729</a>	For the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2729 <a href="https://scottishmedicines.org.uk/media/9018/spesolimab-spevigo-final-feb-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9018/spesolimab-spevigo-final-feb-2025-for-website.pdf</a>	18/03/2025
tafamidis 61mg soft capsules (Vyndaqel®)	<a href="#">2585</a>	For the treatment of wild-type and hereditary transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM).	Routinely available in line with national guidance, SMC 2585 <a href="https://scottishmedicines.org.uk/media/7937/tafamidis-vyndaqel-resub-final-oct-2023-for-website.pdf">https://scottishmedicines.org.uk/media/7937/tafamidis-vyndaqel-resub-final-oct-2023-for-website.pdf</a>	18/03/2025
talazoparib 0.1mg, 0.25mg, 1mg hard capsules (Talzenna®)	<a href="#">2753</a>	In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/03/2025
triamcinolone hexacetonide 20mg/1mL suspension for injection		1) for intra-articular, intrasynovial or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including: - Rheumatoid arthritis - Juvenile Idiopathic Arthritis (JIA) - Osteoarthritis and post-traumatic arthritis - Synovitis, tendinitis, bursitis and epicondylitis 2) for the intraarticular use in children aged 3 – 12 years with Juvenile Idiopathic Arthritis	This medicine is now withdrawn from use/discontinued	18/03/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®)	466/24	[off-label use] for the treatment of immunotherapy-induced colitis in adults who are steroid refractory or who require early steroid sparing management. <b>Restriction:</b> for adults who are refractory to infliximab or those where infliximab is contraindicated.	Routinely available in line with local guidance	18/03/2025